Checkpoint Therapeutics Inc (CKPT) has released an update to notify the public and investors about listing compliance status.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Checkpoint Therapeutics, Inc. has fallen out of compliance with Nasdaq’s Board Independence Rule after Scott Boilen’s departure from its Board on January 31, 2024, leaving a majority of its board members as non-independent. Nasdaq confirmed this non-compliance on February 2, 2024, but it does not affect the company’s stock listing or trading for the time being. Checkpoint Therapeutics must comply with the rule by its next annual shareholders’ meeting or by January 31, 2025, with a deadline of July 29, 2024, if the shareholders’ meeting occurs before that date. The company intends to regain compliance within this cure period.
For further insights into CKPT stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
